Financial Performance - The total revenue for the Group for the year was approximately HK$173.702 million, representing an increase of approximately HK$18.879 million compared to 2022[13]. - The gross profit was approximately HK$56.936 million, an increase of approximately HK$2.702 million compared to 2022[13]. - The profit for the year attributable to the owners of the Company was approximately HK$1.820 million, due to the improvement in the hemodialysis treatment and consultancy service business segment in the PRC[13]. - Total revenue for the financial year ended 31 March 2023 was approximately HK$173.702 million, representing an increase of approximately 12.19% compared to HK$154.823 million in 2022[27]. - Gross profit for the same period was approximately HK$56.936 million, an increase of approximately 4.98% from HK$54.234 million in 2022[27]. - Profit for the year attributable to owners of the Company was approximately HK$1.820 million, a significant recovery from a loss of approximately HK$50.999 million in 2022[27]. - Revenue from the hemodialysis treatment and consultancy service business was approximately HK$121.424 million, representing an increase of 17.16% compared to 2022[31]. - Revenue from the pharmaceutical wholesale and distribution business was approximately HK$52.278 million, a slight increase of approximately 2.14% compared to HK$51.183 million in 2022[32]. Business Strategy and Development - The Group will focus on developing the hemodialysis treatment and consultancy service business through organic growth and acquisitions[16]. - The establishment of new self-operated hemodialysis treatment centres is planned to expand operating scale and market penetration[17]. - The Group believes that the demand for hemodialysis treatment services in the PRC market is still far from being met, indicating significant potential for development[18]. - The Group aims to expand its business scale by studying market potential in other cities and regions in the PRC[103]. - The Group is focusing on establishing new self-operated hemodialysis treatment centers and providing consulting services to hospitals[106]. Financial Position and Ratios - The Group's total cash and cash equivalents as of 31 March 2023 were approximately HK$9.876 million, up from approximately HK$5.768 million in 2022[27]. - The current ratio improved to approximately 2.02 as of 31 March 2023, compared to approximately 1.79 in 2022[65]. - The gearing ratio decreased to approximately 0.13 as of 31 March 2023, down from approximately 0.15 in 2022[66]. - The Group recorded a reversal of allowance for expected credit losses on trade and other receivables of approximately HK$7.499 million for the year ended 31 March 2023[68]. Employee and Workforce Information - As of March 31, 2023, the Group had 202 full-time employees, an increase from 184 in 2022[88]. - Staff costs for the year ended March 31, 2023, amounted to approximately HK$20.221 million, up from approximately HK$19.247 million in 2022, reflecting a year-on-year increase of about 5.06%[89]. - The gender distribution of employees shows 52 males and 150 females, indicating a higher female representation[199]. - The age group distribution reveals 97 employees are below 30 years old, while 5 employees are above 60 years old, reflecting a younger workforce[199]. - The Group's workforce is primarily located in Mainland China, with 192 employees, while 10 are based in Hong Kong[199]. Governance and Compliance - The Group's compliance team is responsible for interpreting and promoting external regulatory requirements to mitigate market risks[79]. - The Group maintains a zero-tolerance approach towards bribery, extortion, fraud, and money laundering[136]. - The Group's governance structure regularly reviews and monitors corporate management policies and practices[136]. - The Board is responsible for overseeing the Group's ESG risk management and setting related targets[129]. - The Group provided anti-corruption training to directors and staff during the Reporting Period to enhance integrity awareness[140]. Environmental, Social, and Governance (ESG) Initiatives - The Group collaborated with a sustainability consultant to identify environmental, social, and governance risks, focusing on climate change and product safety[104]. - The Group is committed to integrating ESG concepts into business development and has identified key sustainability issues such as climate change and product safety[106]. - The Group identified 8 material ESG issues during the Reporting Period, including Wastewater Management, Combatting Climate Change, and Anti-Corruption[158]. - The Group's environmental and social KPIs are disclosed in compliance with the "Comply or Explain" provisions of the Listing Rules[114]. - The Group's whistleblowing policy allows employees to report suspected violations to management[139]. Customer Satisfaction and Quality Control - The Group received no complaints related to products and services during the reporting period, indicating high customer satisfaction[188]. - The Group has established a customer complaint management system to continually improve service quality[187]. - The Group emphasizes drug safety and effectiveness, implementing effective quality control measures throughout procurement, storage, sales, and transportation processes[163]. - The Group's Quality Management Department is responsible for ensuring consistent quality throughout the supply chain and conducts regular internal reviews and risk assessments[179]. - No sold or shipped products were recalled for safety and health reasons during the Reporting Period[180].
万嘉集团(00401) - 2023 - 年度财报